2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reduction
2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
2007
A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma. New England Journal Of Medicine 2007, 357: 2016-2027. PMID: 18003958, DOI: 10.1056/nejmoa073600.Peer-Reviewed Original ResearchConceptsSerum YKL-40 levelsYKL-40 levelsSeverity of asthmaYKL-40Chitinase-like proteinsParis cohortOral corticosteroid useCohort of patientsRescue inhaler useSubgroup of patientsCirculation of patientsCorticosteroid useSevere asthmaAirway remodelingClinical characteristicsExpiratory volumeAcidic mammalian chitinasePatient populationHigh serumAsthmaImmunohistochemical analysisPatientsAnimal modelsLocus of expressionMorphometric quantitation
2005
Yoga intervention for adults with mild-to-moderate asthma: a pilot study
Sabina AB, Williams A, Wall HK, Bansal S, Chupp G, Katz DL. Yoga intervention for adults with mild-to-moderate asthma: a pilot study. Annals Of Allergy Asthma & Immunology 2005, 94: 543-548. PMID: 15945557, DOI: 10.1016/s1081-1206(10)61131-3.Peer-Reviewed Original ResearchConceptsModerate asthmaYoga interventionOutcome measuresMasked clinical trialRescue inhaler useHealth care utilizationMini Asthma QualityQuality of lifeFinal followUsual careAsthma QualityExpiratory volumeInhaler useSymptom diaryTreat analysisCare utilizationSymptom scoresAsthma managementClinical indicesLife QuestionnaireClinical trialsIyengar yogaAsthmaControl groupPilot study